Amit Chunilal Nathwani
Founder presso Freeline Therapeutics Ltd.
Profilo
Founder of Freeline Therapeutics Holdings Plc, Novalgen Ltd.
and Freeline Therapeutics Ltd., Amit Chunilal Nathwani is a British entrepreneur who holds the position of Director & Chief Scientific Officer at Freeline Therapeutics Ltd.
and Chief Executive Officer & Director at Novalgen Ltd.
Dr. Nathwani is also Professor at University College London and Director-Katharine Dormandy Hemophilia Centre at Royal Free Hospital Medical School.
In the past Dr. Nathwani was Independent Director at Freeline Therapeutics Holdings Plc.
Dr. Nathwani received a doctorate from The Open University and an undergraduate degree from the University of Aberdeen.
Posizioni attive di Amit Chunilal Nathwani
Società | Posizione | Inizio |
---|---|---|
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Founder | 01/01/2015 |
University College London | Corporate Officer/Principal | 01/11/2011 |
Royal Free Hospital Medical School | Corporate Officer/Principal | 01/11/2012 |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Founder | 01/01/2019 |
Precedenti posizioni note di Amit Chunilal Nathwani
Società | Posizione | Fine |
---|---|---|
FREELINE THERAPEUTICS HOLDINGS PLC | Founder | 04/04/2023 |
Formazione di Amit Chunilal Nathwani
University of Aberdeen | Undergraduate Degree |
The Open University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 3 |
---|---|
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Freeline Therapeutics Holdings Plc
Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Health Technology |